Pharmaceuticals, Biotechnology and Life Sciences
– Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study;…
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3…
IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Nymox announces that it dismissed the Delaware matter pending against Ascella on…
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster…
TUSCALOOSA, Ala., March 10, 2025 (GLOBE NEWSWIRE) — Druid City Vital Care (“Druid City”) was recently recognized at the Vital…
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation…
All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of…
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025,…
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year ––…
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003…